ContextVision (CONTX) investor relations material

Executive summary

• Revenue grew 8.5% year-over-year to SEK 28.5 million in Q1 2026, driven by increased license sales, new contracts, and portfolio execution in a stabilizing market.

• Underlying revenue growth was approximately 7.4% after accounting for FX effects and refined revenue recognition timing.

• Strategic R&D collaboration with BeamWorks announced to advance AI-powered quantitative ultrasound imaging.

• Strengthened management team with the appointment of Marco Marien Voormolen as CTO and continued progress in clinical development at University of Washington.

• Extended share buyback program until May 2026, reflecting confidence in capital structure.

Financial highlights

• Q1 2026 revenue reached SEK 28.5 million, up from SEK 26.3 million in Q1 2025, an 8.5% increase.

• Adjusted EBITDA was SEK 5.8 million (20.5% margin), up from SEK 2.1 million (8.1% margin) year-over-year.

• Adjusted operating result was SEK 4.0 million (14.1% margin), up from SEK 0.6 million (2.4% margin).

• Adjusted EPS rose to SEK 0.05 from SEK 0.01 in Q1 2025.

• Cash flow from operating activities was SEK 4.3 million, up from SEK 0.3 million; cash balance at period end was SEK 69 million.

Outlook and guidance

• Stable market environment expected for the remainder of 2026, with continued focus on executing the quantitative imaging strategy and capturing partnership and commercial opportunities.

• Positioned to benefit from normalization of procurement cycles in China and ongoing demand for high-quality imaging.